Serum Marker IDs Likely Responders to CAR-T Therapy in Lymphoma – MedPage Today
|
Serum Marker IDs Likely Responders to CAR–T Therapy in Lymphoma
MedPage Today Patients achieving complete, durable remissions in relapsed/refractory non-Hodgkin lymphoma following low-dose conditioning chemotherapy and anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tended to be those with high serum levels of … |
